Education
About Us
Working with TipRanks
Follow Us
BioNTech SE (GB:0A3M)
LSE:0A3M
0A3M Analyst Ratings
Moderate Buy
14 Buy
5 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
0A3M Stock 12 Month Forecast
Average Price Target
$138.74
▲(20.51%Upside)
| Highest Price Target$181.00 | Average Price Target$138.74 | Lowest Price Target$95.81 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Goldman Sachs
$110
Hold
-4.46%
Downside
Initiated
05/29/25
Morgan Stanley
$132
Buy
14.65%
Upside
Reiterated
05/27/25
J.P. Morgan
$120→$116
Hold
0.76%
Upside
Reiterated
05/22/25
H.C. Wainwright
$134
Buy
16.39%
Upside
Reiterated
05/22/25
Truist Financial
―
Buy
―
Reiterated
05/21/25
Jefferies
$149
Buy
29.42%
Upside
Reiterated
05/20/25
Bank of America Securities
$127
Buy
10.31%
Upside
Reiterated
05/14/25
Deutsche Bank
$140
Buy
21.60%
Upside
Reiterated
05/13/25
UBS
$115
Hold
-0.11%
Downside
Reiterated
05/07/25
Evercore ISI
$125
Buy
8.57%
Upside
Reiterated
05/06/25
Berenberg Bank
$130
Buy
12.92%
Upside
Reiterated
05/06/25
TD Cowen
$110
Hold
-4.46%
Downside
Reiterated
05/05/25
We model €1.88B in revenues in the mid range of the guidance as we are concerned about potential label restrictions for Comirnaty in the US (~21% of global sales only) given regulatory scrutiny. Development and commercial preparation for a 2025/26 season variant-adapted COVID-19 vaccine is ongoing. Of note, the first wave of global decisions on strain selection for the upcoming 2025 COVID season are expected to start in the next few weeks in May. While there has been concern that the CDC ACIP vote on COVID booster recommendations in June could narrow the US recommendation to risk base, mgmt notes that US vaccinations in the past few years have already been concentrated in the ~20% of patients who are >65 yo or immunocompromised, and expect little impact to Comirnaty sales.
Canaccord Genuity
$171
Buy
48.53%
Upside
Reiterated
05/05/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Goldman Sachs
$110
Hold
-4.46%
Downside
Initiated
05/29/25
Morgan Stanley
$132
Buy
14.65%
Upside
Reiterated
05/27/25
J.P. Morgan
$120→$116
Hold
0.76%
Upside
Reiterated
05/22/25
H.C. Wainwright
$134
Buy
16.39%
Upside
Reiterated
05/22/25
Truist Financial
―
Buy
―
Reiterated
05/21/25
Jefferies
$149
Buy
29.42%
Upside
Reiterated
05/20/25
Bank of America Securities
$127
Buy
10.31%
Upside
Reiterated
05/14/25
Deutsche Bank
$140
Buy
21.60%
Upside
Reiterated
05/13/25
UBS
$115
Hold
-0.11%
Downside
Reiterated
05/07/25
Evercore ISI
$125
Buy
8.57%
Upside
Reiterated
05/06/25
Berenberg Bank
$130
Buy
12.92%
Upside
Reiterated
05/06/25
TD Cowen
$110
Hold
-4.46%
Downside
Reiterated
05/05/25
We model €1.88B in revenues in the mid range of the guidance as we are concerned about potential label restrictions for Comirnaty in the US (~21% of global sales only) given regulatory scrutiny. Development and commercial preparation for a 2025/26 season variant-adapted COVID-19 vaccine is ongoing. Of note, the first wave of global decisions on strain selection for the upcoming 2025 COVID season are expected to start in the next few weeks in May. While there has been concern that the CDC ACIP vote on COVID booster recommendations in June could narrow the US recommendation to risk base, mgmt notes that US vaccinations in the past few years have already been concentrated in the ~20% of patients who are >65 yo or immunocompromised, and expect little impact to Comirnaty sales.
Canaccord Genuity
$171
Buy
48.53%
Upside
Reiterated
05/05/25
Best Analysts Covering BioNTech SE
1 Month
xxx
Success Rate
16/27 ratings generated profit
Average Return
+2.47%
reiterated a xxx
rating 13 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 59.26% of your transactions generating a profit, with an average return of +2.47% per trade.
3 Months
xxx
Success Rate
13/27 ratings generated profit
Average Return
+1.36%
reiterated a xxx
rating 13 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 48.15% of your transactions generating a profit, with an average return of +1.36% per trade.
1 Year
Success Rate
12/27 ratings generated profit
Average Return
-6.50%
reiterated a buy rating 13 days ago
Copying Robert Burns's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of -6.50% per trade.
2 Years
xxx
Success Rate
9/23 ratings generated profit
Average Return
+22.43%
reiterated a xxx
rating 21 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 39.13% of your transactions generating a profit, with an average return of +22.43% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
0A3M Analyst Recommendation Trends
Rating
Jan 25
Feb 25
Mar 25
Apr 25
May 25
Strong Buy
3
0
6
8
11
Buy
44
27
34
35
46
Hold
11
4
4
4
7
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
58
31
44
47
64
Each month's total comprises the sum of three months' worth of ratings.
0A3M Financial Forecast
0A3M Stock Forecast FAQ
What is GB:0A3M’s average 12-month price target, according to analysts?
Based on analyst ratings, BioNTech SE’s 12-month average price target is 138.74.
What is GB:0A3M’s upside potential, based on the analysts’ average price target?
BioNTech SE has 20.51% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is BioNTech SE a Buy, Sell or Hold?
BioNTech SE has a consensus rating of Moderate Buy, which is based on 14 buy ratings, 5 hold ratings and 0 sell ratings.
What is BioNTech SE’s share price target?
The average share price target for BioNTech SE is 138.74. This is based on 19 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $181.00 ,and the lowest forecast is $95.81. The average share price target represents 20.51% Increase from the current price of $115.13.
The highest analyst share price target is $181.00 ,and the lowest forecast is $95.81. The average share price target represents 20.51% Increase from the current price of $115.13.
What do analysts say about BioNTech SE?
BioNTech SE’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 19 Wall Streets Analysts.
How can I buy shares of BioNTech SE?
To buy shares of GB:0A3M, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.